New Triple-Threat attack on Tough-to-Treat stomach cancers
NCT ID NCT04522336
Summary
This small, early-stage study is testing whether combining an immunotherapy drug (pembrolizumab) with chemotherapy and radiation can help control advanced stomach and esophageal cancers that cannot be surgically removed. The goal is to see if this three-part approach is safe and can shrink or eliminate the cancer. The study will involve about 16 participants with this specific type of cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLINICAL STAGE III GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.